Angiostatin is a naturally occurring inhibitor of angiogenesis that is being developed as a drug to fight cancer. In this study we reveal that EL-4 tumors established in mice rapidly develop resistance to angiostatin gene therapy by upregulating hypoxia-inducible pathways. Angiostatin initially delayed tumor growth for 6 days by reducing blood vessel density. However, tumors quickly responded by upregulating the production of hypoxia-inducible factor-1a (HIF-1a) and its effector vascular endothelial growth factor (VEGF) in response to increasing tumor hypoxia, leading to restored angiogenesis and rapid tumor growth. Theoretically, blockade of HIF-1 should prevent resistance to anti-angiogenic therapy by preventing a tumor from responding to induced hypoxia. Antisense HIF-1a inhibited the expression of HIF-1a and of the HIF-1 effectors VEGF, glucose transporter-1 and lactate dehydrogenase. As a monotherapy, it was effective in eradicating small 0.1 cm diameter tumors, but only delayed the growth of large 0.4 cm diameter tumors. In contrast, timed injection of a combination of angiostatin and antisense HIF-1a plasmids completely eradicated large EL-4 tumors within 2 weeks, and prevented upregulation of hypoxia-inducible pathways induced by angiostatin. The data indicate that blocking hypoxia-inducible pathways by antisense HIF-1a can circumvent hypoxia-induced drug resistance and thereby augment the efficacy of anti-angiogenic therapies.
Introduction
Solid tumors need to establish blood vessels to grow beyond 1-2 mm and metastasize, which provides the rationale for anti-angiogenic approaches to cancer therapy. 1 It had been believed that targeting tumor blood vessels should not lead to drug resistance as endothelial cells, unlike cancer cells, are genetically stable. 2, 3 However, human clinical trials of anti-angiogenic agents to date have been disappointing as they show only modest effects on the overall survival of cancer patients. 4 Tumors respond and become resistant to anti-angiogenic therapies although in most cases the mechanisms have not been ascertained. Higher quantities of basic fibroblast growth factor were detected in mice, which had been treated with vascular endothelial factor (VEGF) receptor antibody, accompanied by reactivation of tumor angiogenesis. 5 Increased plasma VEGF levels were observed in clinical trials of anti-angiogenic tyrosine kinase inhibitors. 6, 7 Endostatin-mediated anti-angiogenic therapy of murine mammary carcinomas caused a compensatory increase in tumoral VEGF mRNA expression. 8 Indeed, VEGF and other angiogenic factors are being considered as soluble markers for the detection of hypoxia as an indication of the apparent efficacy of anti-angiogenic treatment. [9] [10] [11] Angiostatin, a 38 kDa protein containing several internal kringle domains of plasminogen, inhibits endothelial cell proliferation and migration, and suppresses tumor growth and metastasis. [12] [13] [14] However, angiostatin as a monotherapy to combat cancer has not progressed further than a phase 1 clinical trial. 15 Human neuroblastoma and breast xenografts were found to be resistant to the effects of adenovirally delivered angiostatin. 16, 17 Angiostatin was apparently not able to counteract the very high level of VEGF released by the tumors, suggesting that it was susceptible to drug resistance. It is important to identify and successfully block the pathways responsible for tumor resistance to angiostatin if this promising drug is to be of clinical benefit.
Hypoxic microenvironments, which are a feature of many solid tumors, could theoretically be amplified by anti-angiogenic therapy as the latter suppresses blood supply and oxygen to the tumor. Hypoxia orchestrates a wide spectrum of molecular pathways, and is a major cause of tumor resistance to radiotherapy and chemotherapy. 18, 19 Hypoxia-inducible factor-1 (HIF-1), the 'master regulator' of classical hypoxia-inducible pathways, 20 mediates the adaptation of cancer cells to the hypoxic environment by controlling the expression of hundreds of genes, 21, 22 including VEGF, glycolytic enzymes and glucose transporters. HIF-1, formed by the assembly of HIF-1a and HIF-1b, binds hypoxia-response elements in the promoters of the above genes. 20 HIF-1b is constitutively expressed, whereas HIF-1a is rapidly degraded during normoxia, and dramatically stabilized and activated during hypoxia, by oxygen sensing and signaling processes. 23 We have previously reported that antisense HIF-1a gene therapy enhances immunotherapy to eradicate EL-4 lymphomas in mice. 24 In addition, we recently showed that antisense HIF-1a gene therapy enhances the efficacy of doxorubicin and transcatheter arterial embolization to combat liver cancers. 25, 26 In the present study we examine tumor resistance to angiostatin gene therapy and test the hypothesis that blockade of HIF-1a to inhibit hypoxia-inducible pathways will prevent acquired drug resistance. This is the first study to analyze whether targeting HIF-1 has the potential to improve the therapeutic efficacy of an anti-angiogenic cancer drug.
Materials and methods
Mice, cell lines, plasmids and antibodies Male C57BL/6 mice, 6-8 weeks old, were obtained from the Animal Resource Unit, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. The EL-4 thymic lymphoma, which is of C57BL/6(H-2 b ) origin, was purchased from the American Type Culture Collection (Rockville, MD). It was cultured at 37 1C in Dulbecco's modified Eagle's medium (Gibco BRL, Grand Island, NY) supplemented with 10% fetal calf serum, 50 U ml -1 penicillin/streptomycin, 2 mM L-glutamine and 1 mM pyruvate. The pcDNA3 expression vectors encoding the kringle 1-4 form of mouse angiostatin, 27 and an antisense version of the 5 0 end of HIF-1a have been described previously. 24 The antibodies (Abs) used include those against plasminogen (recognizing kringles 1-3 of angiostatin; Calbiochem-Novabiochem Corp., San Diego, CA), VEGF (Ab-1; Lab Vision Corp., Fremont, CA), mouse HIF-1a (H1a67; Novus Biologicals, Inc., Littleton, CO), CD31 (MEC13.3 Ab; Pharmingen, San Diego, CA), glucose transporter 1 and lactate dehydrogenase A (Santa Cruz Biotechnology, Santa Cruz, CA). Pimonidazole hydrochloride (Hypoxyprobe-1) and an anti-Hypoxyprobe-1 Ab were obtained from Chemicon (Temecula, CA).
Gene transfer of expression plasmids and measurement of tumor growth Purified plasmids were diluted to 1 mg ml -1 in a solution of 5% glucose in 0.01% Triton X-100, and mixed in a ratio of 1:3 (wt:wt) with DOTAP cationic liposomes (Boehringer Mannheim, Mannheim, Germany), as described previously. 24, 27 Tumors were established by injection of 2 Â 10 5 EL-4 tumor cells into the right flank of mice, and growth was determined by measuring two perpendicular diameters. Animals were killed when tumors reached more than 1 cm in diameter, in accord with the Animal Ethics Approval (University of Auckland). Tumors were injected with 100 mg (100 ml) of expression plasmid upon reaching either 0.1 or 0.4 cm in diameter. For combinational treatment, reagents were delivered in a timed manner, in which the angiostatin plasmid was injected first, followed by antisense HIF-1a plasmid after 24 h. Empty pcDNA3 vector served as a plasmid control. All experiments included six mice per group, and each experiment was repeated at least once.
Evaluation of tumor hypoxia
The EL-4 tumors in a group of three mice were injected with angiostatin plasmid or empty pcDNA3 vector when the tumors reached 0.4 cm in diameter, as above. At 7 days after injection, the mice received an intravenous injection of pimonidazole hydrochloride (Hypoxyprobe-1) dissolved in phosphate-buffered saline at a dose of 120 mg kg -1 . The mice were killed 24 h later and the tumors were harvested, sectioned and immunostained with an anti-Hypoxyprobe-1 Ab.
Immunohistochemistry
Tumor cryosections (10 mm) were incubated overnight with primary antibodies, followed by subsequent incubation with appropriate secondary antibodies (VECTAS-TAIN Universal Quick kit; Vector Laboratories, Burlingame, CA), and developed with Sigma FAST DAB (3, 3 0 -diaminobenzidine tetrahydrochloride) and CoCl 2 enhancer tablets (Sigma-Aldrich New Zealand Ltd., Auckland, New Zealand). Sections were counterstained with Mayer's hematoxylin.
Western blot analysis
Tumors were excised, homogenized in a protein lysate buffer and protein samples (50 mg) were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were electrophoretically transferred to nitrocellulose Hybond C extra membranes, and the membranes were incubated with primary antibodies and subsequently with horseradish peroxidase-conjugated secondary antibodies. Immunoreactivity was developed by enhanced chemiluminescence (Amersham International, Buckingham, UK) and exposure to X-ray film. Band density was quantified using Sigma ScanPro software (Systat Software Inc., San Jose, CA).
Assessment of tumor vascularity
Tumor vascularity was measured as described previously. 24, 27 In brief, tumor sections (10 mm) prepared 4 days after plasmid injection were immunostained with an anti-CD31 antibody. Stained blood vessels were counted in five blindly chosen random fields (0.155 mm 2 ) at Â 40 magnification, and the mean of the highest three counts was calculated. The concentric circles method was used to assess vascularity, 24, 27 in which 5 to 6 tumor sections were analyzed for each plasmid-injected tumor.
Detection of apoptotic cells in situ
Frozen tumor sections (6 mm) were fixed, permeabilized and incubated with the terminal deoxynucleotidyl transferase dUTP nick end labeling reagent for 60 min at 37 1C and examined by fluorescence microscopy. Adjacent sections were counterstained with hematoxylin and eosin. The total number of apoptotic cells in 10 randomly selected fields was counted. The apoptosis index was calculated as the percentage of positive staining cells, namely, AI ¼ number of apoptotic cells Â 100/total number of nucleated cells.
Statistical analysis
Results are expressed as mean values þ s.d. The Student's t-test was used for evaluating statistical significance, in which a P-value of o0.05 denotes statistical significance. Figure 1c , panels 7-9) increased in response to therapy. HIF-1a was detected in the cytoplasm in addition to the nucleus, in which cytoplasmic HIF-1 presumably results from increased synthesis of HIF-1a needed to maintain or increase the levels of nuclear HIF-1. 28 Western blot analysis of tumor homogenates confirmed the latter findings. Thus, gene transfer of angiostatin upregulated the expression of HIF-1a and VEGF by 1.0-fold in 4 days after gene transfer and by twofold in 7 days after gene transfer, respectively (Figure 1d ). The hypoxia marker pimonidazole hydrochloride was intravenously injected 7 days after gene transfer into mice bearing EL-4 tumors to confirm that upregulated expression of HIF-1a and VEGF was in response to angiostatin-induced increases in tumor hypoxia. As shown in Figure 1e , the staining of pimonidazole hydrochloride was increased in angiostatin gene-injected tumors compared with tumors injected with empty plasmid control.
Results

Hypoxia
Antisense HIF-1a downregulates hypoxia-inducible pathways, eradicates small tumors and suppresses the growth of large tumors Small EL-4 tumors, 0.1 cm in diameter, were established as above, and injected with 100 mg of antisense HIF-1a plasmid or empty control vector. Tumors in the control group grew rapidly, reaching 0.9 cm in size 18 days after gene transfer. In contrast, tumors injected with the antisense HIF-1a plasmid rapidly regressed and completely disappeared 10 days after gene transfer (Figure 2a ). Antisense HIF-1 gene therapy was less effective against large 0.4 cm in diameter tumors. It significantly (Po0.01) suppressed tumor growth for 10 days (Figure 2b ), but eventually all tumors re-grew, reaching 0.9 cm in diameter within 3 weeks. The ineffectiveness of antisense HIF-1 therapy against large tumors was not the result of an inadequate dosage of plasmid, as increasing the plasmid dosage to 250 mg did not significantly increase the inhibition of tumor growth (data not shown), as reported previously. 24 Antisense HIF-1 therapy strongly inhibited endogenous HIF-1a expression, and expression of the downstream effectors VEGF, glucose transporter 1 and lactate dehydrogenase A, as measured by western blot analysis of homogenates of large tumors prepared 2 days after gene transfer (Figure 2c ).
Antisense HIF-1a prevents acquired tumor resistance to angiostatin Gene transfer of antisense HIF-1a and angiostatin was combined to determine whether antisense HIF-1a would effectively prevent angiostatin-mediated activation of hypoxia-inducible pathways that promote tumor growth and result in acquired resistance to angiostatin. Large EL-4 tumors, 0.4 cm in diameter, were first injected with 100 mg of angiostatin plasmid, and then with 100 mg of the (Figure 3a) . Mice remained tumorfree for 2 months (data not shown). In contrast, control tumors grew unchecked. The growth of tumors treated with angiostatin was initially suppressed, but tumors subsequently grew very rapidly as in Figure 1b . The growth of tumors treated with antisense HIF-1a was significantly suppressed for at least 9 days, as described in Figure 2b . Combinational gene transfer increased the expression of angiostatin and decreased the expression of HIF-1a and its effectors VEGF, glucose transporter 1 and lactate dehydrogenase A, as measured by western blot analysis of tumor homogenates prepared 4 and 10 days after gene transfer (Figure 3b ). Angiostatin expression and silencing of HIF-1a and its effectors was maintained for at least 10 days after gene transfer.
Antisense HIF-1a and angiostatin synergize to inhibit tumor angiogenesis Sections prepared from the tumors described in Figure 3b were stained with an anti-CD31 Ab to visualize tumor blood vessels (Figure 4a ). Angiostatin gene therapy significantly (Po0.01) reduced tumor vessel density 4 days after gene transfer (Figures 4a and b) . In contrast, by day 10 it was clear that the vessel density of tumors had rebounded and was slightly increased compared with that of control tumors treated with empty vector. This result was in spite of the fact that tumoral expression of angiostatin remained elevated at day 10 ( Figure 3b) , and even at day 12 (data not shown). At day 4 the median distance to the nearest CD31-labeled vessel from an array of points within tumors treated with angiostatin was significantly increased compared with that for tumors treated with empty vector, but by day 10 there was no difference between angiostatin-treated tumors and controls (Figure 4c ). Combinational therapy significantly (Po0.01) reduced vessel density by day 4, with a further significant (Po0.001) reduction on day 10 (Figures 4a  and b) . The median distance to the nearest CD31-labeled vessel from an array of points within tumors was significantly increased on both day 4 (Po0.01) and day 10 (Po0.001) compared with that for control tumors (Figure 4c ).
Antisense HIF-1 a and angiostatin synergize to induce tumor cell apoptosis Sections prepared from the tumors described in Figure 3b were stained with the terminal deoxynucleotidyl transferase dUTP nick end labeling agent to determine the extent of programmed death of tumor cells. Only small numbers of apoptotic cells were detected in tumors injected with empty plasmid (Figures 5a and b) . In contrast, tumor apoptosis was almost doubled on day 4 after injection of angiostatin plasmid, but had declined significantly by day 10. The combination of angiostatin and antisense HIF-1a plasmids significantly increased tumor apoptosis on day 4 (Po0.01), with a further increase on day 10 (Po0.001; Figures 5a and b) .
Discussion
Currently, dozens of promising anti-angiogenic drugs that target different facets of endothelial function are undergoing evaluation in clinical trials. The results of trials to date have been disappointing, with only modest increases in overall patient survival being achieved, even when antiangiogenic drugs have been combined with chemotherapy. It has to be appreciated that anti-angiogenic therapy leads to hypoxia, which serves as a platform for drug resistance. In this study we have shown that angiostatin gene therapy initially delays the growth of tumors accompanied by reduced tumoral blood vessel density, but within 1 week of therapy tumors recover and re-grow more rapidly than control tumors. At first glance these Antisense HIF-1a prevents resistance to angiostatin X Sun et al results might seem inexplicable, given that angiostatin expression was still highly elevated 12 days after gene therapy. The explanation seems to reside in the finding that the expression of HIF-1a and VEGF was elevated within 4 days of angiostatin therapy and further increased by day 7, accompanied by increased tumor blood vessel density. Thus, tumors upregulated hypoxia-inducible pathways in response to angiostatin-imposed hypoxia, releasing pro-angiogenic factors that effectively competed with angiostatin and promoted angiogenesis and accelerated tumor growth. We had earlier reported that VEGF expression was elevated in response to angiostatin in a study examining the ability of angiostatin to augment cancer immunotherapy. 27 In accord, and as mentioned earlier, basic fibroblast growth factor and VEGF protein and/or mRNA levels increased in response to antiangiogenic therapy using either antibodies and tyrosine kinase inhibitors against VEGF receptors or endostatin. [5] [6] [7] The treatment of rectal cancer patients with the anti-VEGF monoclonal antibody bevacizumab led to significant decreases in blood flow and microvessel density; however, plasma levels of VEGF and the angiogenic factor placental growth factor markedly increased. Thus, hypoxia-induced resistance is a feature encountered with a variety of anti-angiogenic agents.
Non-hypoxia pathways may also potentially contribute to tumor resistance to angiostatin. Thus, Shojaei et al. 29 reported that EL-4 tumors were refractory to anti-VEGF Ab therapy because of their ability to recruit CD11b þ Gr1 þ myeloid cells that confer resistance. Although not analyzed in this study, CD11b þ Gr1 þ myeloid cells may also contribute to the failure of angiostatin gene therapy, although the likelihood is lessened by the fact that angiostatin and anti-VEGF Ab exert their anti-angiogenic effects through different mechanisms. Nevertheless, in this scenario, antisense HIF-1a therapy may prevent tumor cells from expressing cytokines or chemoattractants involved in the mobilization of myeloid cells.
In contrast to the very modest affects of angiostatin, a single injection of antisense HIF-1a was able to completely eradicate small tumors, due in part to the downregulation of expression of VEGF, glucose transporter 1 and lactate dehydrogenase A. The latter two proteins are required for the high glycolytic rates of cancer cells, and hence are important for the bioenergetics of tumor growth. In accord, antisense HIF-1a was found to downregulate the expression of proliferating cell nuclear antigen, and inhibited cellular proliferation in liver tumors. 25 We have previously reported that antisense HIF-1a also induces natural killer cell-dependent rejection of small tumors. 24 Antisense HIF-1a was not able to eradicate larger tumors. It is plausible that the large tumors developed HIF-1a-independent pathways of angiogenesis, 30 although this possibility was not analyzed. Oncogenes such as K-ras activate transcription pathways that upregulate pro-angiogenic factors independently of HIF-1. 31 It is important that anti-angiogenic therapy involves combinations of anti-angiogenic agents, given that multiple HIF-dependent and HIF-independent angiogenic pathways exist. In this study we have shown that a combination therapy involving the timed gene transfer of angiostatin and antisense HIF-1a is effective in eradicating large tumors, whereas the monotherapies are ineffective. Antisense HIF-1a prevents acquired resistance to angiostatin. If HIF-1-independent angiogenic pathways exist for EL-4 lymphomas, then they are not effective in competing with angiostatin to promote tumor angiogenesis. Abdollahi et al. 32 proposed the concept of combining 'direct' and 'indirect' angiogenesis inhibitors. They classified direct angiogenesis inhibitors as those that directly target microvascular endothelial cells and prevent them from responding to pro-angiogenic stimuli. This class presumably would also include vascular disrupting agents that can destroy established tumor vessels, such as the tubulin-binding agent combretastatin, and the flavonoid 5,6-dimethylxanthenone-4-acetic acid. 33 In contrast, indirect angiogenesis inhibitors target pro-angiogenic proteins and their receptors and/or their interaction. With them, the combination of endostatin (direct inhibitor) with SU5416 (indirect inhibitor; a vascular endothelial growth factor receptor 2 receptor tyrosine kinase inhibitor) was more effective than the respective monotherapies against human prostate, lung and glioma cancer xenografts. In the present study angiostatin represents the 'direct' inhibitor, and antisense HIF-1a could be considered to represent the 'ultimate' indirect inhibitor as it prevents the upregulation of hypoxiainducible pathways and pro-angiogenic proteins. Angiostatin seems to be able to compete effectively with HIF-1-independent pathways that remain after antisense HIF-1a therapy.
It is important to consider the in vitro effects of angiostatin and HIF1a silencing on EL-4 cell viability and proliferation. Koshiji et al. 34 took advantage of an oxygen-dependent degradation domain-deficient HIF-1a (DODD), which is stable and functional in normoxia, and showed that HIF-1a, even in the absence of a hypoxic signal, induces cell cycle arrest by antagonizing Myc activity, resulting in derepression of p21cip1. Given this result, antisense HIF-1a would be expected to downregulate HIF-1, thereby releasing tumor cells from the growth-inhibitory effects of HIF-1. In contrast, antisense HIF-1a inhibits the growth of tumors, suggesting that tumor cells that are growth inhibited by HIF-1a nevertheless provide important factors such as angiogenic factors to aid the survival and growth of tumors cells presumably located in anoxic regions of the tumor. In accord, we have recently shown that antisense HIF-1a downregulated the expression of proliferating cell nuclear antigen and inhibited cellular proliferation in liver tumors in situ. 25 Regarding the effects of angiostatin, we have previously shown that EL-4 cells transfected with an angiostatin-expressing plasmid and empty vector control had identical growth rates in vitro, indicating that angiostatin has no detectable effect on the viability and proliferation of EL-4 cells. 27 Gene therapy as used in this study provides a rapid means of assessing the utility of therapeutic targets, either alone or in combination, but is not necessarily the best clinical approach. The appropriate approach for translating the results to the clinic will require additional work, but one would imagine that the combination of recombinant angiostatin 15 with a specific small molecule inhibitor 35, 36 of HIF-1a would be an excellent first approach. In summary, the combination of anti-angiogenic agents such as angiostatin that directly inhibit endothelial cells, with agents that antagonize HIF-1, overcomes compensatory angiogenic responses responsible for drug resistance, and warrants investigation as a therapeutic approach in the treatment of cancer. 
